# Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

> **NCT01098474** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 301 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** GSK's investigational vaccine 692342
- **BIOLOGICAL:** Tritanrix™ HB+Hib
- **BIOLOGICAL:** Prevnar™
- **BIOLOGICAL:** Polio Sabin™
- **BIOLOGICAL:** Menjugate™

## Key facts

- **NCT ID:** NCT01098474
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-07
- **Primary completion:** 2011-04-30
- **Final completion:** 2012-03-16
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2019-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01098474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01098474, "Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01098474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*